Dicot Pharma AB DICOT
Updated: 9 Aug 2026
No signal published yet
We already track Dicot Pharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Dicot Pharma AB? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Dicot Pharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In June 2026, Dicot Pharma announced that it received FDA clearance to initiate the first part of its Phase 2b study with LIB-01 in the U.S. In the same month, the company completed a rights issue and directed share issue raising approximately SEK 231 million before transaction costs.
What Firelda Watch includes for Dicot Pharma AB
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Dicot Pharma AB? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Dicot Pharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more